<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39428981</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1750-2659</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Influenza and other respiratory viruses</Title><ISOAbbreviation>Influenza Other Respir Viruses</ISOAbbreviation></Journal><ArticleTitle>Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children.</ArticleTitle><Pagination><StartPage>e70022</StartPage><MedlinePgn>e70022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/irv.70022</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The aim of this study is to determine the incidence and risk factors associated with COVID-19 hospitalization among unvaccinated children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Children aged 0- &lt; 18 years, members of Kaiser Permanente Northern California (KPNC), were followed from March 1, 2020, until the earliest occurrence of: chart-confirmed COVID-19 hospitalization, disenrollment from KPNC, age 18 years, receipt of COVID-19 vaccine, death, or study end (December 31, 2022). We calculated the incidence rate of hospitalization by SARS-CoV-2 variant period and by age group. We determined risk factors for hospitalization using Poisson regression. We also conducted descriptive analyses of hospitalized cases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 1,107,799 children, 423 were hospitalized for COVID-19 during follow-up. The incidence of hospitalization increased with each new SARS-CoV-2 variant and was highest among children aged &lt; 6 months. Among the &lt; 6-month-olds, the incidence rate per 100,000 person-months was 7 during predelta, 13.3 during delta, and 22.4 during omicron. Black (RR = 2.05, 95% CI: 1.33-3.16) and Hispanic children (RR = 1.82, 95% CI: 1.34-2.46) and children with any comorbidities were at high risk of hospitalization (RR = 3.81, 95% CI: 2.94-4.95). Overall, 20.3% of hospitalized children were admitted to an intensive care unit (ICU), but ICU admission was 36.1% among 12- &lt; 18-year-olds. The majority of ICU admits (91.8%) had no comorbidities.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Children too young to be vaccinated had the highest incidence of COVID-19 hospitalization, while adolescents had the highest proportion of ICU admissions. To prevent severe disease in children and adolescents, everyone eligible should be vaccinated.</AbstractText><CopyrightInformation>© 2024 The Author(s). Influenza and Other Respiratory Viruses published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zerbo</LastName><ForeName>Ousseny</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-8380-6215</Identifier><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Timbol</LastName><ForeName>Julius</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goddard</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Layefsky</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Pat</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fireman</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Dao</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greenhow</LastName><ForeName>Tara L</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Pediatrics Infectious Diseases, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Nicola P</ForeName><Initials>NP</Initials><AffiliationInfo><Affiliation>Vaccine Study Center, Kaiser Permanente Northern California, Oakland, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AI168373-02</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>75D30120C07765</GrantID><Acronym>CC</Acronym><Agency>CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Influenza Other Respir Viruses</MedlineTA><NlmUniqueID>101304007</NlmUniqueID><ISSNLinking>1750-2640</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">pediatric infections</Keyword><Keyword MajorTopicYN="N">unvaccinated</Keyword></KeywordList><CoiStatement>Dr. Klein has received research support from Pfizer for COVID vaccine clinical trials and research support from GlaxoSmithKline, Sanofi Pasteur, Merck, Pfizer, and Protein Science (now Sanofi Pasteur) for unrelated studies. The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>13</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>10</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>21</Day><Hour>3</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39428981</ArticleId><ArticleId IdType="pmc">PMC11491685</ArticleId><ArticleId IdType="doi">10.1111/irv.70022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
American Academy of Pediatrics and the Children's Hospital Association
. “Children and COVID‐19:State Data Report. A joint report from the American Academy of Pediatrics and the Children's Hospital Association,” accessed October 5, 2022, https://downloads.aap.org/AAP/PDF/AAPandCHA‐ChildrenandCOVID‐19StateDataReport9.29.22FINAL.pdf?_ga=2.255000394.335550773.1665001859‐370326403.1636740765.</Citation></Reference><Reference><Citation>Smith B. K., Janowski A. B., Danis J. E., et al., “Seroprevalence of SARS‐CoV‐2 Antibodies in Children and Adults in St. Louis, Missouri, USA,” mSphere 6, no. 1 (2021): e01207‐20, 10.1128/mSphere.01207-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mSphere.01207-20</ArticleId><ArticleId IdType="pmc">PMC7860990</ArticleId><ArticleId IdType="pubmed">33536325</ArticleId></ArticleIdList></Reference><Reference><Citation>Carreno J. M., Wagner A. L., Monahan B., et al., “SARS‐CoV‐2 Serosurvey Across Multiple Waves of the COVID‐19 Pandemic in New York City Between 2020‐2023,” Nature Communications 15, no. 1 (2024): 5847, 10.1038/s41467-024-50052-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-50052-2</ArticleId><ArticleId IdType="pmc">PMC11239669</ArticleId><ArticleId IdType="pubmed">38992013</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien S. C., Cole L. D., Albanese B. A., et al., “SARS‐CoV‐2 Seroprevalence Compared With Confirmed COVID‐19 Cases Among Children, Colorado, USA, May‐July 2021,” Emerging Infectious Diseases 29, no. 5 (2023): 929–936, 10.3201/eid2905.221541.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2905.221541</ArticleId><ArticleId IdType="pmc">PMC10124638</ArticleId><ArticleId IdType="pubmed">36972709</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L. R., Rose E. B., Horwitz S. M., et al., “Multisystem Inflammatory Syndrome in U.S. Children and Adolescents,” new England Journal of Medicine 383, no. 4 (2020): 334–346, 10.1056/NEJMoa2021680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021680</ArticleId><ArticleId IdType="pmc">PMC7346765</ArticleId><ArticleId IdType="pubmed">32598831</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L. R., Tenforde M. W., Friedman K. G., et al., “Characteristics and Outcomes of US Children and Adolescents With Multisystem Inflammatory Syndrome in Children (MIS‐C) Compared With Severe Acute COVID‐19,” Jama 325, no. 11 (2021): 1074–1087, 10.1001/jama.2021.2091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.2091</ArticleId><ArticleId IdType="pmc">PMC7905703</ArticleId><ArticleId IdType="pubmed">33625505</ArticleId></ArticleIdList></Reference><Reference><Citation>Havers F. P., Whitaker M., Self J. L., et al., “Hospitalization of Adolescents Aged 12–17 Years With Laboratory‐Confirmed COVID‐19 ‐ COVID‐NET, 14 States, March 1, 2020‐April 24, 2021,” MMWR Morbidity and Mortality Weekly Report 70, no. 23 (2021): 851–857, 10.15585/mmwr.mm7023e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7023e1</ArticleId><ArticleId IdType="pmc">PMC8191866</ArticleId><ArticleId IdType="pubmed">34111061</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim L., Whitaker M., O'Halloran A., et al., “Hospitalization Rates and Characteristics of Children Aged &lt;18 Years Hospitalized With Laboratory‐Confirmed COVID‐19 ‐ COVID‐NET, 14 States, March 1–July 25, 2020,” MMWR Morbidity and Mortality Weekly Report 69, no. 32 (2020): 1081–1088, 10.15585/mmwr.mm6932e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6932e3</ArticleId><ArticleId IdType="pmc">PMC7440125</ArticleId><ArticleId IdType="pubmed">32790664</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston L. E., Chevinsky J. R., Kompaniyets L., et al., “Characteristics and Disease Severity of US Children and Adolescents Diagnosed With COVID‐19,” JAMA Network Open 4, no. 4 (2021): e215298, 10.1001/jamanetworkopen.2021.5298.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.5298</ArticleId><ArticleId IdType="pmc">PMC8035649</ArticleId><ArticleId IdType="pubmed">33835179</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghadas S. M., Vilches T. N., Zhang K., et al., “The Impact of Vaccination on Coronavirus Disease 2019 (COVID‐19) Outbreaks in the United States,” Clinical Infectious Diseases 73, no. 12 (2021): 2257–2264, 10.1093/cid/ciab079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab079</ArticleId><ArticleId IdType="pmc">PMC7929033</ArticleId><ArticleId IdType="pubmed">33515252</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks K. J., Whitaker M., Agathis N. T., et al., “Hospitalization of Infants and Children Aged 0–4 Years With Laboratory‐Confirmed COVID‐19 ‐ COVID‐NET, 14 States, March 2020–February 2022,” MMWR. Morbidity and Mortality Weekly Report 71, no. 11 (2022): 429–436, 10.15585/mmwr.mm7111e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7111e2</ArticleId><ArticleId IdType="pmc">PMC8942304</ArticleId><ArticleId IdType="pubmed">35298458</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamid S., Woodworth K., Pham H., et al., “COVID‐19‐Associated Hospitalizations Among U.S. Infants Aged &lt;6 Months ‐ COVID‐NET, 13 States, June 2021–August 2022,” MMWR. Morbidity and Mortality Weekly Report 71, no. 45 (2022): 1442–1448, 10.15585/mmwr.mm7145a3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7145a3</ArticleId><ArticleId IdType="pmc">PMC9707352</ArticleId><ArticleId IdType="pubmed">36355608</ArticleId></ArticleIdList></Reference><Reference><Citation>Head J. R., Collender P. A., Leon T. M., et al., “COVID‐19 Vaccination and Incidence of Pediatric SARS‐CoV‐2 Infection and Hospitalization,” JAMA Network Open 7, no. 4 (2024): e247822, 10.1001/jamanetworkopen.2024.7822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2024.7822</ArticleId><ArticleId IdType="pmc">PMC11040406</ArticleId><ArticleId IdType="pubmed">38652476</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson E. J., Creech C. B., Berthaud V., et al., “Evaluation of mRNA‐1273 Vaccine in Children 6 Months to 5 Years of Age,” new England Journal of Medicine 387, no. 18 (2022): 1673–1687, 10.1056/NEJMoa2209367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209367</ArticleId><ArticleId IdType="pmc">PMC9634866</ArticleId><ArticleId IdType="pubmed">36260859</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleming‐Dutra K. E., Britton A., Shang N., et al., “Association of Prior BNT162b2 COVID‐19 Vaccination With Symptomatic SARS‐CoV‐2 Infection in Children and Adolescents During Omicron Predominance,” Jama 327, no. 22 (2022): 2210–2219, 10.1001/jama.2022.7493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.7493</ArticleId><ArticleId IdType="pmc">PMC9107063</ArticleId><ArticleId IdType="pubmed">35560036</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan F. L., Nguyen J. L., Singh T. G., et al., “Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age,” JAMA Network Open 5, no. 12 (2022): e2246915, 10.1001/jamanetworkopen.2022.46915.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.46915</ArticleId><ArticleId IdType="pmc">PMC9856252</ArticleId><ArticleId IdType="pubmed">36515946</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein N. P., Stockwell M. S., Demarco M., et al., “Effectiveness of COVID‐19 Pfizer‐BioNTech BNT162b2 mRNA Vaccination in Preventing COVID‐19‐Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5–17 Years ‐ VISION Network, 10 States, April 2021–January 2022,” MMWR Morbidity and Mortality Weekly Report 71, no. 9 (2022): 352–358, 10.15585/mmwr.mm7109e3.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7109e3</ArticleId><ArticleId IdType="pmc">PMC8893336</ArticleId><ArticleId IdType="pubmed">35239634</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz F. M., Sher L. D., Sabharwal C., et al., “Evaluation of BNT162b2 Covid‐19 Vaccine in Children Younger Than 5 Years of age,” new England Journal of Medicine 388, no. 7 (2023): 621–634, 10.1056/NEJMoa2211031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2211031</ArticleId><ArticleId IdType="pmc">PMC9947923</ArticleId><ArticleId IdType="pubmed">36791162</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S. Y., Frankland T. B., Slezak J. M., et al., “Effectiveness Associated With BNT162b2 Vaccine Against Emergency Department and Urgent Care Encounters for Delta and Omicron SARS‐CoV‐2 Infection Among Adolescents Aged 12 to 17 Years,” JAMA Network Open 5, no. 8 (2022): e2225162, 10.1001/jamanetworkopen.2022.25162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.25162</ArticleId><ArticleId IdType="pmc">PMC9350713</ArticleId><ArticleId IdType="pubmed">35921109</ArticleId></ArticleIdList></Reference><Reference><Citation>Valier M. R., Elam‐Evans L. D., Mu Y., et al., “Racial and Ethnic Differences in COVID‐19 Vaccination Coverage Among Children and Adolescents Aged 5–17 Years and Parental Intent to Vaccinate Their Children ‐ National Immunization Survey‐Child COVID Module, United States, December 2020–September 2022,” MMWR. Morbidity and Mortality Weekly Report 72, no. 1 (2023): 1–8, 10.15585/mmwr.mm7201a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7201a1</ArticleId><ArticleId IdType="pmc">PMC9815155</ArticleId><ArticleId IdType="pubmed">36602930</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen K. H., Levisohn A., McChesney C., Vasudevan L., Bednarczyk R. A., and Corlin L., “Disparities in Child and Adolescent COVID‐19 Vaccination Coverage and Parental Intent Toward Vaccinations for Their Children and Adolescents,” Annals of Medicine 55, no. 1 (2023): 2232818, 10.1080/07853890.2023.2232818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890.2023.2232818</ArticleId><ArticleId IdType="pmc">PMC10351440</ArticleId><ArticleId IdType="pubmed">37449878</ArticleId></ArticleIdList></Reference><Reference><Citation>
California, Department of Public Health
. “Tracking Variants,” accessed November 19, 2021, https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/COVID‐19/COVID‐Variants.aspx.</Citation></Reference><Reference><Citation>Carlsen E. O., Magnus M. C., Oakley L., et al., “Association of COVID‐19 Vaccination During Pregnancy With Incidence of SARS‐CoV‐2 Infection in Infants,” JAMA Internal Medicine 182, no. 8 (2022): 825–831, 10.1001/jamainternmed.2022.2442.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2022.2442</ArticleId><ArticleId IdType="pmc">PMC9161123</ArticleId><ArticleId IdType="pubmed">35648413</ArticleId></ArticleIdList></Reference><Reference><Citation>Danino D., Ashkenazi‐Hoffnung L., Diaz A., et al., “Effectiveness of BNT162b2 Vaccination During Pregnancy in Preventing Hospitalization for Severe Acute Respiratory Syndrome Coronavirus 2 in Infants,” Journal of Pediatrics 254 (2023): 48–53.e1, 10.1016/j.jpeds.2022.09.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2022.09.059</ArticleId><ArticleId IdType="pmc">PMC9568274</ArticleId><ArticleId IdType="pubmed">36252864</ArticleId></ArticleIdList></Reference><Reference><Citation>Halasa N. B., Olson S. M., Staat M. A., et al., “Maternal Vaccination and Risk of Hospitalization for Covid‐19 Among Infants,” new England Journal of Medicine 387, no. 2 (2022): 109–119, 10.1056/NEJMoa2204399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204399</ArticleId><ArticleId IdType="pmc">PMC9342588</ArticleId><ArticleId IdType="pubmed">35731908</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbo O., Ray G. T., Fireman B., et al., “Maternal SARS‐CoV‐2 Vaccination and Infant Protection Against SARS‐CoV‐2 During the First Six Months of Life,” Nature Communications 14, no. 1 (2023): 894, 10.1038/s41467-023-36547-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-36547-4</ArticleId><ArticleId IdType="pmc">PMC9974935</ArticleId><ArticleId IdType="pubmed">36854660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Li X., Zhang L., Wan S., Zhang L., and Zhou F., “SARS‐CoV‐2 Omicron Variant: Recent Progress and Future Perspectives,” Signal Transduction and Targeted Therapy 7, no. 1 (2022): 141, 10.1038/s41392-022-00997-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00997-x</ArticleId><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K., Nainu F., Frediansyah A., et al., “Global Emerging Omicron Variant of SARS‐CoV‐2: Impacts, Challenges and Strategies,” Journal of Infection and Public Health 16, no. 1 (2023): 4–14, 10.1016/j.jiph.2022.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.11.024</ArticleId><ArticleId IdType="pmc">PMC9675435</ArticleId><ArticleId IdType="pubmed">36446204</ArticleId></ArticleIdList></Reference><Reference><Citation>Modes M. E., Directo M. P., Melgar M., et al., “Clinical Characteristics and Outcomes Among Adults Hospitalized With Laboratory‐Confirmed SARS‐CoV‐2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance ‐ One Hospital, California, July 15–September 23, 2021, and December 21, 2021‐January 27, 2022,” MMWR Morbidity and Mortality Weekly Report 71, no. 6 (2022): 217–223, 10.15585/mmwr.mm7106e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7106e2</ArticleId><ArticleId IdType="pmc">PMC8830624</ArticleId><ArticleId IdType="pubmed">35143466</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X., Li S., Yu H., et al., “Epidemiological, Comorbidity Factors With Severity and Prognosis of COVID‐19: A Systematic Review and Meta‐Analysis,” Aging (Albany NY) 12, no. 13 (2020): 12493–12503, 10.18632/aging.103579.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103579</ArticleId><ArticleId IdType="pmc">PMC7377860</ArticleId><ArticleId IdType="pubmed">32658868</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison S. L., Fazio‐Eynullayeva E., Lane D. A., Underhill P., and Lip G. Y. H., “Comorbidities Associated With Mortality in 31,461 Adults With COVID‐19 in the United States: A Federated Electronic Medical Record Analysis,” PLoS Medicine 17, no. 9 (2020): e1003321, 10.1371/journal.pmed.1003321.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003321</ArticleId><ArticleId IdType="pmc">PMC7482833</ArticleId><ArticleId IdType="pubmed">32911500</ArticleId></ArticleIdList></Reference><Reference><Citation>Zerbo O., Lewis N., Fireman B., et al., “Population‐Based Assessment of Risks for Severe COVID‐19 Disease Outcomes,” Influenza and Other Respiratory Viruses 16, no. 1 (2022): 159–165, 10.1111/irv.12901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/irv.12901</ArticleId><ArticleId IdType="pmc">PMC8652998</ArticleId><ArticleId IdType="pubmed">34432371</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey L. C., Razzaghi H., Burrows E. K., et al., “Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States,” JAMA Pediatrics 175, no. 2 (2021): 176–184, 10.1001/jamapediatrics.2020.5052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.5052</ArticleId><ArticleId IdType="pmc">PMC7684518</ArticleId><ArticleId IdType="pubmed">33226415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotzinger F., Santiago‐Garcia B., Noguera‐Julian A., et al., “COVID‐19 in Children and Adolescents in Europe: A Multinational, Multicentre Cohort Study,” Lancet Child Adolesc Health 4, no. 9 (2020): 653–661, 10.1016/S2352-4642(20)30177-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(20)30177-2</ArticleId><ArticleId IdType="pmc">PMC7316447</ArticleId><ArticleId IdType="pubmed">32593339</ArticleId></ArticleIdList></Reference><Reference><Citation>Graff K., Smith C., Silveira L., et al., “Risk Factors for Severe COVID‐19 in Children,” Pediatric Infectious Disease Journal 40, no. 4 (2021): e137–e145, 10.1097/INF.0000000000003043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003043</ArticleId><ArticleId IdType="pubmed">33538539</ArticleId></ArticleIdList></Reference><Reference><Citation>Kompaniyets L., Agathis N. T., Nelson J. M., et al., “Underlying Medical Conditions Associated With Severe COVID‐19 Illness Among Children,” JAMA Network Open 4, no. 6 (2021): e2111182, 10.1001/jamanetworkopen.2021.11182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.11182</ArticleId><ArticleId IdType="pmc">PMC8185607</ArticleId><ArticleId IdType="pubmed">34097050</ArticleId></ArticleIdList></Reference><Reference><Citation>Saatci D., Ranger T. A., Garriga C., et al., “Association Between Race and COVID‐19 Outcomes Among 2.6 Million Children in England,” JAMA Pediatrics 175, no. 9 (2021): 928–938, 10.1001/jamapediatrics.2021.1685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2021.1685</ArticleId><ArticleId IdType="pmc">PMC8218232</ArticleId><ArticleId IdType="pubmed">34152371</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuller C. C., Cosgrove A., Shinde M., et al., “Treatment and Care Received by Children Hospitalized With COVID‐19 in a Large Hospital Network in the United States, February 2020 to September 2021,” PLoS ONE 18, no. 7 (2023): e0288284, 10.1371/journal.pone.0288284.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0288284</ArticleId><ArticleId IdType="pmc">PMC10335660</ArticleId><ArticleId IdType="pubmed">37432951</ArticleId></ArticleIdList></Reference><Reference><Citation>
WHO
. 2024. “Strategic Advisory Group of Experts (SAGE) Interim statement on COVID‐19 vaccination for children,” accessed September 20, 2024, https://www.who.int/news/item/11‐08‐2022‐interim‐statement‐on‐covid‐19‐vaccination‐for‐children.</Citation></Reference><Reference><Citation>Naleway A. L., Groom H. C., Crawford P. M., et al., “Incidence of SARS‐CoV‐2 Infection, Emergency Department Visits, and Hospitalizations Because of COVID‐19 Among Persons Aged &gt;/=12 Years, by COVID‐19 Vaccination Status ‐ Oregon and Washington, July 4–September 25, 2021,” MMWR. Morbidity and Mortality Weekly Report 70, no. 46 (2021): 1608–1612, 10.15585/mmwr.mm7046a4.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7046a4</ArticleId><ArticleId IdType="pmc">PMC8601415</ArticleId><ArticleId IdType="pubmed">34793417</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M. G., Stenehjem E., Grannis S., et al., “Effectiveness of Covid‐19 Vaccines in Ambulatory and Inpatient Care Settings,” new England Journal of Medicine 385, no. 15 (2021): 1355–1371, 10.1056/NEJMoa2110362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2110362</ArticleId><ArticleId IdType="pmc">PMC8451184</ArticleId><ArticleId IdType="pubmed">34496194</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson M. G., Burgess J. L., Naleway A. L., et al., “Prevention and Attenuation of Covid‐19 With the BNT162b2 and mRNA‐1273 Vaccines,” new England Journal of Medicine 385, no. 4 (2021): 320–329, 10.1056/NEJMoa2107058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2107058</ArticleId><ArticleId IdType="pmc">PMC8262622</ArticleId><ArticleId IdType="pubmed">34192428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohnert A. S., Kumbier K., Rowneki M., et al., “Adverse Outcomes of SARS‐CoV‐2 Infection With Delta and Omicron Variants in Vaccinated Versus Unvaccinated US Veterans: Retrospective Cohort Study,” BMJ 381 (2023): e074521, 10.1136/bmj-2022-074521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-074521</ArticleId><ArticleId IdType="pubmed">37220941</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>